| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2617 | Hydrocaffeoyl-fasudil 1d | Novel multitarget Fasudil derivative, inducing the NRF2 signature, promoting the expression of the antioxidant response enzymes HO-1 and NQO1, via a KEAP1-dependent mechanism |
|
| DCC2618 | Hydrolapachol | Novel potent and selective inhibitor of Schistosoma mansoni dihydroorotate dehydrogenase (SmDHODH) |
|
| DCC2619 | Hydroxyellipticine-1a | Novel selective r(CGG)exp probe, improving pre-mRNA splicing defects, inhibiting formation of nuclear inclusions and RANT in a FXTAS cellular model |
|
| DCC2620 | Hydroxymatairesinol | Natural antioxidant and anti-cancer agent, blocking the MAPK/NF-κB and activating Nrf2/HO-1 |
|
| DCC2621 | Hydroxytriolein | Novel anticancer agent, inhibiting lung cancer cell proliferation via a PKCa and ERK1/2 dependent mechanism |
|
| DCC2622 | Hymenidin | Natural antagonist of serotonergic receptors and inhibitor of CDK5/p25 and GSK-3ß |
|
| DCC2623 | Hys-32 | Novel analogue of combretastatin A-4, enhancing connexin43 expression |
|
| DCC2624 | Hz-ma Hybrid 11b | Novel potent and selective inhibitor of fat mass obesity-associated protein (FTO), being selectively over alkylation repair homologue 5 (ALKBH5), another DNA/RNA demethylase |
|
| DCC2625 | Iag-10 | Novel potent and selective inhibitor of human DNA polymerase kappa (hpol κ) |
|
| DCC2626 | Ianthellamide A | Selective kynurenine-3-hydroxylase inhibitor |
|
| DCC2627 | Ianthelliformisamine A Tfa Salt | Antibiotic enhancer against resistant Gram-negative bacteria |
|
| DCC2628 | Ianthelliformisamine B Tfa Salt | Antibiotic enhancer against resistant Gram-negative bacteria |
|
| DCC2629 | Ianthelliformisamine C Tfa Salt | Antibiotic enhancer against resistant Gram-negative bacteria |
|
| DCC2630 | Iap-in-1 | Novel antagonist of IAP (inhibitor of apoptosis protein) |
|
| DCC2631 | Iaxo-101 | Novel inhibitor of the cluster of differentiation 14 innate immunity pathway |
|
| DCC2632 | Ibe-667 | Novel activator of LFA-1-ICAM-1 binding |
|
| DCC2633 | Ibl-302 | First-in-class triple-acting PIM/PI3K/mTOR inhibitor, demonstrating single-agent, anti-tumour efficacy in suppression of pAKT, pmTOR and pBAD in the SKBR-3, BT-474 and HCC-1954 HER2+/PIK3CA-mutated cell lines |
|
| DCC2634 | Ibpr001 Hydrochloride | Novel Aurora kinase inhibitor |
|
| DCC2635 | Ibpr002 | Novel Aurora kinase inhibitor, revealing mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules |
|
| DCC2636 | Ibrutinib-bfl | Novel fluorescent irreversible inhibitor of Bruton's tyrosine kinase (BTK) |
|
| DCC2637 | Ibs399024 | Novel HDAC6-selective inhibitor |
|
| DCC2638 | Ic2418 | MmpL3 inhibitor, being active against drug-resistant Mycobacterium tuberculosis |
|
| DCC2639 | ica-27243 | Neuronal Kv7 potassium channel activator |
|
| DCC2640 | Icagen-4 | Inhibitor of voltage-gated K(+) (Kv) channels Kv1.3 and Kv1.5 |
|
| DCC2641 | Ical-36 | Novel inhibitor of CALP, exhibiting affinity of 22.6 ± 8.0 μM for CALP and no interaction with the NHERF PDZ domains |
|
| DCC2642 | icec0943 | Novel selective inhibitor of CDK7 |
|
| DCC2643 | Ici-185282 | Potent thromboxane receptor antagonist |
|
| DCC2644 | Ici-56780 | Antimalarial agent, displaying blood schizonticidal activity against P.berghei |
|
| DCC2645 | Iclaprim | Novel selective bacterial dihydrofolate inhibitor, antibiotic, actively against Gram positive organisms |
|
| DCC2646 | Icl-ccic-0019 | Novel potent and selective inhibitor of choline kinase alpha (CHKA) |
|
